<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772524</url>
  </required_header>
  <id_info>
    <org_study_id>ALD403-CLIN-002</org_study_id>
    <nct_id>NCT01772524</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of ALD403</brief_title>
  <official_title>A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alder Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alder Biopharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single&#xD;
      dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of ALD403: laboratory variables, ECG and adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Physical Examination&#xD;
Vital signs&#xD;
12-lead ECG (electrocardiogram)&#xD;
Clinical laboratory tests (hematology, chemistry)&#xD;
Number of participants with Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetics of ALD403</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cmax - maximum plasma concentration&#xD;
Tmax - Time to achieve maximum plasma concentration&#xD;
AUC - Area under the plasma concentration-time curve&#xD;
T1/2 - Elimination half-life&#xD;
Vz - Volume of distribution&#xD;
CL - Clearance&#xD;
Bioavailability&#xD;
Plasma levels of unbound ALD403</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ALD403</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in frequency of migraine days compared to baseline&#xD;
Responder rate&#xD;
Migraine hours&#xD;
Migraine episodes&#xD;
Migraine severity&#xD;
Use of acute migraine medications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>ALD403</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV Dose on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single IV infusion on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD403</intervention_name>
    <arm_group_label>ALD403</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Diagnosis of migraine at ≤ 50 years of age (ICHD-II, 2004 Section 1)&#xD;
&#xD;
          -  History of migraine ≥ 12 months with&#xD;
&#xD;
               -  ≥ 5 and ≤ 14 migraine days in each 28 day period in the 3 months prior to&#xD;
                  screening&#xD;
&#xD;
               -  use of acute migraine medications ≤ 14 days per 28 day period and, within those&#xD;
                  days, ≤ 10 days of triptan use per 28 day period in the 3 months prior to&#xD;
                  screening and the 28 day period of completion of eDiary prior to randomization&#xD;
&#xD;
          -  Women of child-bearing potential and males with partners of child-bearing potential&#xD;
             must agree to use adequate contraception (oral or injectable [depot] estrogen, and/or&#xD;
             progestogen, or selective estrogen receptor modulator contraceptive therapeutic,&#xD;
             intrauterine contraceptive device, or double barrier method [e.g., condom and&#xD;
             diaphragm or spermicidal gel]). Non-childbearing potential is defined as&#xD;
             post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least&#xD;
             3 months before screening&#xD;
&#xD;
          -  Any hormonal therapy (e.g., oral contraceptives, hormone replacement therapy) use is&#xD;
             stable and ongoing for at least 3 months prior to screening and during the 28 day&#xD;
             period from screening to randomization&#xD;
&#xD;
          -  Agree not to post any personal medical data related to the trial or information&#xD;
             related to the trial on any website or social media site (e.g., Facebook, Twitter)&#xD;
             until the trial has been completed&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Confounding pain syndromes including fibromyalgia, chronic musculoskeletal (e.g., low&#xD;
             back pain), psychiatric conditions, dementia, or major neurological disorders other&#xD;
             than migraine that interfere with the participation in the trial&#xD;
&#xD;
          -  Diagnosis of complicated migraine, chronic tension-type headache, hypnic headache,&#xD;
             hemicrania continua, new daily persistent headache, basilar, hemiplegic, or familial&#xD;
             hemiplegic migraine&#xD;
&#xD;
          -  Regular use (greater than 7 days) of prophylactic headache medication (any preventive&#xD;
             medication or supplement with evidence of efficacy from at least 1 placebo-controlled&#xD;
             trial) within 3 months, or onabotulinumtoxin A within 6 months prior to screening or&#xD;
             during the 28 day period prior to randomization&#xD;
&#xD;
          -  Cardiac surgery or cardiac symptoms within 3 months of screening and during the 28 day&#xD;
             period prior to randomization&#xD;
&#xD;
          -  Suspected or diagnosis of hypertension with or without antihypertensive treatment&#xD;
&#xD;
          -  Any ongoing co-morbidity that in the opinion of the Investigator will interfere with&#xD;
             the participation in the trial&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 39 at screening&#xD;
&#xD;
          -  Pregnant, breast-feeding, or planning to become pregnant during the trial&#xD;
&#xD;
          -  Patients who have used opioids &gt; 5 days for the treatment of pain in more than 2 of&#xD;
             the 6 months prior to screening or in the 28 day period prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alder Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premiere Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACT Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Roslindale</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedVadis Research</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Headache &amp; Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPRI</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates of Arlington</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Lifetree</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidewater Integrated Medical Research</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Women's: Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine Disorders</keyword>
  <keyword>Phase 1</keyword>
  <keyword>ALD403</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

